Google
×
Nov 3, 2010 · This study suggests that the level of Aβ38 can potentially contribute in the diagnostic distinction between AD and DLB when combined with Aβ42.
People also ask
Dive into the research topics of 'CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies'. Together they form a unique fingerprint.
The data clearly demonstrate that CSF Aβ peptide patterns vary in a disease-specific manner between Alzheimer's disease, DLB, PDD and neuropsychiatric diseases.
Oct 10, 2019 · CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2011;82(2):160–4. Article ...
This study suggests that the level of Aβ38 can potentially contribute in the diagnostic distinction between AD and DLB when combined with Aβ42. Single measures ...
Jun 18, 2020 · Here, we aimed to identify novel CSF biomarkers for DLB using a high-throughput proteomic approach.
May 8, 2020 · Moreover, CSF Aβ42/Aβ38 ratio might be helpful in the differentiation between AD and dementia with Lewy bodies (DLB) [76] and other non-AD ...
Jul 9, 2013 · Results: The CSF Aβ1-42/Aβ1-40 ratio increased discrimination of AD from PDD and DLB compared with either of the two Aβ biomarkers individually.
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. ... amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Jan 1, 2016 · Further, the Aβ42/Aβ40 and Aβ42/Aβ38 ratios showed increased accuracy compared to Aβ42 when distinguishing AD from dementia with Lewy bodies or ...